ESR1 and breast cancer: Additionally, we explored if the combination of a PI3Ki plus a CDK4/6i has therapeutic potential in ER+ and in HER2+ BC with primary or acquired resistance to CDK4/6i, and its association with the PIK3CA, ESR1, RB1-mutation status.